SCHEMBL2269708

SCHEMBL2269708

Fc1ccc(-c2nc(Cl)c3c(n2)CCC3)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
ADORA2A P29274 1/20 0.48
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
ACHE P22303 6/20 0.43
BCHE P06276 5/20 0.43
GRIN1 Q05586 5/20 0.43
GRIN2A Q12879 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
HPGD P15428 2/20 0.42
RAB9A P51151 2/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTGS2 P35354 1/20 0.40
TP53 P04637 2/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7500873 0.97 KDM4E (0.45) KDM4EADORA2AHTR2AHTR2CHTR2B
SCHEMBL5734234 0.87 TP53 (0.45) KDM4EACHEBCHEGRIN1GRIN2A
SCHEMBL15921329 0.84 ACHE (0.43) ACHEBCHEGRIN1GRIN2ASMN1; SMN2
SCHEMBL2269571 0.84 ALDH1A1 (0.44) KDM4EACHEBCHEGRIN1GRIN2A
SCHEMBL2273843 0.83 LMNA (0.52) KDM4EADORA2AACHEBCHESMN1; SMN2
SCHEMBL6075340 0.83 TP53 (0.48) KDM4EACHEBCHEGRIN1GRIN2A
SCHEMBL6076028 0.81 KDM4E (0.47) KDM4EACHEBCHEGRIN1GRIN2A
SCHEMBL6077222 0.81 ACHE (0.40) ACHEBCHEGRIN1GRIN2ASMN1; SMN2
SCHEMBL5733814 0.80 MAPK1 (0.43) KDM4EADORA2AHTR2AHTR2CHTR2B
SCHEMBL5733821 0.80 HRH2 (0.51) KDM4EACHEBCHEGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
WO-2010028174-A1 NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators GATAD2A, GATAD2B, RUNX1 KDM4E 309/4885ADORA2A 2200/4885HTR2A 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.